HARRISBURG, Pa., Aug. 15, 2018 /PRNewswire/ -- Nearly 5,000 diabetes educators may be inclined to say "yes"—gut bacteria are at the root of the disease after they visit the Prebiotin booth at this year's American Association of Diabetes Educators (AADE) Annual Conference (held in Baltimore, MD, August 17-20).
With every study that focuses on diabetes and the microbiome, research is more definite that if you have diabetes, you also have an unhealthy mix of bacteria in your gut.
Researchers have found that so much of the disease, especially type 2 diabetes, is largely the result of excess body weight and problems associated with gut bacteria. Numerous studies with oligofructose-enriched inulin (OEI), the ingredient in Prebiotin, demonstrate that regular supplementation allows beneficial bacteria like bifidobacteria and lactobacilli to flourish, while reducing the abundance of Firmicutes and other undesirable microbes.
Other studies show that by supporting this healthy shift of the microbial balance in the gut microbiome, regular supplementation with Prebiotin can reduce the inflammation and "leaky gut" conditions that result in increased disease risk, obesity, and illnesses like diabetes.
In a current NIH study that focuses on finding therapeutic means to reduce inflammation and prolong survival of patients with end stage renal disease (ESRD), researchers chose Prebiotin® Prebiotic Fiber to study the effect of the supplement on the gut microbiome profile. Due to early positive results, researchers are discussing a larger study to further explore the role of prebiotic fiber in reducing inflammation. Diabetes is one of the main risk factors for ESRD.
"Ongoing research is beginning to unravel the role of the microbiome in the development and subsequent clinical course of type 2 diabetes," says Prebiotin Medical Director, F. Wilson Jackson, MD, gastroenterologist. "As we understand this interplay, we are able to harness the power of the microbiome to further treat type 2 diabetes. The potential to modulate the gut microbiome offers a new therapeutic approach. These are exciting and promising times for patients with the disease."
About 500 million people worldwide suffer from some form of diabetes. In the United States, 30.3 million Americans—or 9.4 percent of the population—have diabetes, according to the Centers for Disease Control and Prevention (CDC) in a 2017 report. More than a third of U.S. adults have prediabetes and aren't aware of it. In 2015, diabetes was the 7th leading cause of death in the U.S.
Since diabetes has such a major impact on public health, Prebiotin recognizes and supports the role of the American Association of Diabetes Educators [AADE] in teaching health care professionals and patients alike about the most current and best practices for diabetes care.
"We hope those attending the AADE conference recognize our product has a legitimate, researched impact on the microbiome and can play an important role in therapeutic responses to dysbiosis, the microbial imbalance in the body leading to inflammation—and diabetes," says Greg Cooper, Prebiotin Director of Product and Business Development.
Prebiotin CEO Ron E. Walborn Jr. and Greg Cooper, Director of Product and Business Development, will be available to answer questions at the event.
"We provide an all-natural prebiotic option that improves health and well-being, including reducing risk and symptoms of diabetes, while promoting healthy weight loss," says Prebiotin CEO Ron Walborn. "The AADE18 conference is a perfect fit for us."
Jackson GI Medical/Prebiotin was founded by visionary prebiotic pioneer Dr. Frank Jackson in 2008, and is dedicated to the responsible development and marketing of medically credible nutritional supplements backed by third-party research. Located in Harrisburg, PA, the company can be reached at 855-466-3488 or online at http://www.prebiotin.com.